Enlivex Reports Positive Interim Data From Allocetra In Severe Knee Osteoarthritis

June 17, 2024 — 09:08 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Enlivex Therapeutics Ltd. (ENLV), Monday announced a positive interim data from a Phase I/II clinical trial of Allocetra in patients with severe knee osteoarthritis patients indicated for knee replacement surgery.

The company said it tried a single Allocetra injection to the knee as a potential last resort alternative for pain resolution and knee functionality in lieu of knee-replacement surgery.

A total of nine patients have been enrolled and treated with a single Allocetra injection to the knee and evaluated for at least three months following treatment.

At the three-month follow up, out of the nine patients enrolled, eight of them reported an improvement in their knee pain compared to their baseline pain prior to treatment, while 33 of the patients reported complete pain relief.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Enlivex Reports Positive Interim Data From Allocetra In Severe Knee Osteoarthritis

Tags

Latest Articles